{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T02:06:59Z","timestamp":1788660419335,"version":"build-2803163510"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Finasteride is commonly utilized in clinical practice for treating androgenetic alopecia, but real-world data regarding the long-term safety of its 0adverse events(AEs) remains incomplete, necessitating ongoing supplementation. This study aims to evaluate the AEs associated with finasteride use, based on data from the US Food and Drug Administration Adverse Event Reporting System (FAERS), to contribute to its safety assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed AE reports associated with finasteride from the US Food and Drug Administration Adverse Event Reporting System database, covering the period from the first quarter of 2004 to the first quarter of 2024. We assessed the safety of finasteride medication and AEs using four proportional disproportionality analyses: reported odds ratio (ROR), proportionate reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPN), and Multi-Item Gamma Poisson Shrinkage (MGPS). These methods were used to evaluate whether there is a significant association between finasteride drug use and AEs. To investigate potential safety issues related to drug use, we further analyzed the similarities and differences in the onset time and AEs by sex, as well as the similarities and differences in AEs by age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11,557 AE reports in which finasteride was the primary suspected drug were analysed. The majority of patients were male (86.04%) and a significant proportion were young adults aged 18-45 years (27.22%). A total of 73 different AEs were categorised into 7 system organ classes (SOCs), with common AEs including erectile dysfunction and sexual dysfunction. In addition, we identified previously unlisted AEs, including Peyronie\u2019s disease and post-5\u03b1 reductase inhibitor syndrome. Of the reported AEs, 102 occurred in men and 7 in women, with depression and anxiety being significant AEs observed in both sexes. When analysed by age group, there were 17 AEs in patients aged \u2264\u200918 years, 157 in patients aged 18-65 years and 133 in patients aged \u2265\u200965 years. Common AEs in all age groups included erectile dysfunction, decreased libido, depression, suicidal ideation, psychotic disturbances and attention disorders. The median time to onset of all AEs was 61 days, with the majority occurring within the first month of treatment. Notably, a significant number of AEs persisted beyond one year of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of our study uncovered both known and novel AEs associated with finasteride medication. Some of these AEs were identical to the specification, and some of them signaled AEs that were not demonstrated in the specification. In addition, some AEs showed variations based on sex and age in our study. Consequently, our findings offer valuable insights for future research on the safety of finasteride medication and are anticipated to enhance its safe use in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0309849","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:47:32Z","timestamp":1742863652000},"page":"e0309849","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Multidimensional assessment of adverse events of finasteride\uff1aa real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1661-9775","authenticated-orcid":true,"given":"Xiaoling","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0254-9588","authenticated-orcid":true,"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"issue":"1","key":"pone.0309849.ref001","doi-asserted-by":"crossref","first-page":"136-141.e5","DOI":"10.1016\/j.jaad.2017.02.054","article-title":"The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis","volume":"77","author":"A Adil","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0309849.ref002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaad.2024.03.019","article-title":"Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study","volume":"91","author":"KC Lauck","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"pone.0309849.ref003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4103\/NJM.NJM_61_22","article-title":"Androgenetic Alopecia","volume":"31","author":"AO Enitan","year":"2022","journal-title":"Nigerian J Med"},{"key":"pone.0309849.ref004","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdin.2023.07.005","article-title":"Androgenetic alopecia: An update","volume":"13","author":"S Ntshingila","year":"2023","journal-title":"JAAD Int"},{"key":"pone.0309849.ref005","article-title":"Male androgenetic alopecia","volume-title":"Endotext","author":"L Asfour","year":"2000"},{"issue":"2","key":"pone.0309849.ref006","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jdv.17738","article-title":"Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial","volume":"36","author":"BM Piraccini","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"pone.0309849.ref007","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1038\/s41467-020-19249-z","article-title":"Structure of human steroid 5\u03b1-reductase 2 with the anti-androgen drug finasteride","volume":"11","author":"Q Xiao","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0309849.ref008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome: A surmountable challenge for clinicians","volume":"113","author":"AM Traish","year":"2020","journal-title":"Fertil Steril"},{"issue":"12","key":"pone.0309849.ref009","doi-asserted-by":"crossref","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","article-title":"Association of 5\u03b1-reductase inhibitors with dementia, depression, and suicide","volume":"5","author":"M Garcia-Argibay","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"pone.0309849.ref010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11930-018-0161-6","article-title":"The post-finasteride syndrome: Clinical manifestation of drug-induced epigenetics due to endocrine disruption","volume":"10","author":"AM Traish","year":"2018","journal-title":"Curr Sex Health Rep"},{"issue":"3","key":"pone.0309849.ref011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11154-015-9319-y","article-title":"Adverse effects of 5\u03b1-reductase inhibitors: What do we know, don\u2019t know, and need to know?","volume":"16","author":"AM Traish","year":"2015","journal-title":"Rev Endocr Metab Disord"},{"key":"pone.0309849.ref012","unstructured":"Merck Supplementary file."},{"issue":"2","key":"pone.0309849.ref013","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/andr.13122","article-title":"How routine pharmacovigilance failed to identify finasteride\u2019s persistent sexual side effects","volume":"10","author":"MS Irwig","year":"2022","journal-title":"Andrology"},{"key":"pone.0309849.ref014","doi-asserted-by":"crossref","first-page":"1259611","DOI":"10.3389\/fphar.2023.1259611","article-title":"Drug-induced QT prolongation and torsade de pointes: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database","volume":"14","author":"D Li","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"pone.0309849.ref015","doi-asserted-by":"crossref","first-page":"e0260980","DOI":"10.1371\/journal.pone.0260980","article-title":"Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database","volume":"16","author":"J Nagai","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"pone.0309849.ref016","first-page":"819-829.e2","article-title":"Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"RJ Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"pone.0309849.ref017","doi-asserted-by":"crossref","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: A disproportionality analysis of the FDA Adverse Event Reporting System","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0309849.ref018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40261-024-01346-2","article-title":"Thromboembolic events associated with epidermal growth factor receptor tyrosine kinase inhibitors: A pharmacovigilance analysis of the US FDA Adverse Event Reporting System (FAERS) Database","volume":"44","author":"X Yang","year":"2024","journal-title":"Clin Drug Investig"},{"key":"pone.0309849.ref019","doi-asserted-by":"crossref","first-page":"102199","DOI":"10.1016\/j.arr.2024.102199","article-title":"Recent trends in treatment strategies for Alzheimer's disease and the challenges: A topical advancement","volume":"94","author":"N Liu","year":"2024","journal-title":"Ageing Res Rev"},{"key":"pone.0309849.ref020","doi-asserted-by":"crossref","first-page":"1290975","DOI":"10.3389\/fphar.2024.1290975","article-title":"A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system","volume":"15","author":"M Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0309849.ref021","article-title":"A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system","volume":"15","author":"M Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0309849.ref022","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"F Zou","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0309849.ref023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/pds.5555","article-title":"More extreme duplication in FDA Adverse Event Reporting System detected by literature reference normalization and fuzzy string matching","volume":"32","author":"E Hung","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0309849.ref024","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: A real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"F Zou","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0309849.ref025","doi-asserted-by":"crossref","first-page":"1288362","DOI":"10.3389\/fphar.2024.1288362","article-title":"Comparing the difference of adverse events with HER2 inhibitors: A study of the FDA adverse event reporting system (FAERS)","volume":"15","author":"Y Bao","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0309849.ref026","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14740338.2023.2251888","article-title":"Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"23","author":"T Wu","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"pone.0309849.ref027","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bcp.15336","article-title":"Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System","volume":"89","author":"B Wu","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pone.0309849.ref028","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40272-023-00613-7","article-title":"Toxicity spectrum of anti-GD2 immunotherapy: A real-world study leveraging the US Food and Drug Administration Adverse Event Reporting System","volume":"26","author":"G Wang","year":"2024","journal-title":"Paediatr Drugs"},{"issue":"10","key":"pone.0309849.ref029","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/14740338.2024.2309225","article-title":"Hematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS","volume":"23","author":"X Yu","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0309849.ref030","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"F Zou","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0309849.ref031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","article-title":"Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022","volume":"17","author":"Y Du","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"pone.0309849.ref032","doi-asserted-by":"crossref","first-page":"530","DOI":"10.25259\/IJDVL_949_2021","article-title":"Clinical and metabolic characteristics of males with early-onset androgenetic alopecia","volume":"89","author":"K Vinay","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"pone.0309849.ref033","doi-asserted-by":"crossref","first-page":"e0299212","DOI":"10.1371\/journal.pone.0299212","article-title":"Factors associated with early-onset androgenetic alopecia: A scoping review","volume":"19","author":"L-P Liu","year":"2024","journal-title":"PLoS One"},{"key":"pone.0309849.ref034","doi-asserted-by":"crossref","first-page":"e3020","DOI":"10.7717\/peerj.3020","article-title":"Persistent erectile dysfunction in men exposed to the 5\u03b1-reductase inhibitors, finasteride, or dutasteride","volume":"5","author":"T Kiguradze","year":"2017","journal-title":"PeerJ"},{"issue":"7","key":"pone.0309849.ref035","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/jdv.15548","article-title":"Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study","volume":"33","author":"RS Haber","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"pone.0309849.ref036","doi-asserted-by":"crossref","first-page":"101114","DOI":"10.1016\/j.yfrne.2023.101114","article-title":"Post-finasteride syndrome and post-ssri sexual dysfunction: Two clinical conditions apparently distant, but very close","volume":"72","author":"S Giatti","year":"2024","journal-title":"Front Neuroendocrinol"},{"issue":"1","key":"pone.0309849.ref037","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaad.2024.03.019","article-title":"Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study","volume":"91","author":"KC Lauck","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"pone.0309849.ref038","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/phar.1612","article-title":"Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: A pharmacovigilance study","volume":"35","author":"AK Ali","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"1","key":"pone.0309849.ref039","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","article-title":"Investigation of suicidality and psychological adverse events in patients treated with finasteride","volume":"157","author":"D-D Nguyen","year":"2021","journal-title":"JAMA Dermatol"},{"key":"pone.0309849.ref040","article-title":"Beliefs and counseling practices among dermatologists regarding sexual and other adverse effects of finasteride","author":"MS Irwig","year":"2023","journal-title":"Int J Impot Res"},{"issue":"1","key":"pone.0309849.ref041","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1038\/s41598-023-32356-3","article-title":"Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study","volume":"13","author":"M Laanani","year":"2023","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0309849.ref042","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40265-023-01880-x","article-title":"Androgenetic alopecia: Therapy update","volume":"83","author":"S Devjani","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"pone.0309849.ref043","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/13548506.2023.2242049","article-title":"Psychosocial impact of androgenetic alopecia on men: A systematic review and meta-analysis","volume":"29","author":"H Frith","year":"2024","journal-title":"Psychol Health Med"},{"issue":"6","key":"pone.0309849.ref044","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1159\/000505151","article-title":"Finasteride and suicide: A postmarketing case series","volume":"236","author":"MS Irwig","year":"2020","journal-title":"Dermatology"},{"issue":"2","key":"pone.0309849.ref045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12020-018-1593-5","article-title":"Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?","volume":"61","author":"S Giatti","year":"2018","journal-title":"Endocrine"},{"key":"pone.0309849.ref046","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fendo.2011.00090","article-title":"The neurosteroid progesterone underlies estrogen positive feedback of the LH surge","volume":"2","author":"P Micevych","year":"2011","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"pone.0309849.ref047","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1111\/jsm.12269","article-title":"Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious\/depressive symptomatology","volume":"10","author":"RC Melcangi","year":"2013","journal-title":"J Sex Med"},{"issue":"9","key":"pone.0309849.ref048","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jsxm.2021.05.009","article-title":"Differential gene expression in post-finasteride syndrome patients","volume":"18","author":"S Howell","year":"2021","journal-title":"J Sex Med"},{"issue":"10","key":"pone.0309849.ref049","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1007\/s40618-024-02345-y","article-title":"Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level","volume":"47","author":"S Giatti","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"pone.0309849.ref050","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.euf.2024.04.009","article-title":"Association of 5\u03b1-reductase inhibitors with depression and suicide: A mini systematic review and meta-analysis","volume":"10","author":"A Uleri","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"6","key":"pone.0309849.ref051","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamadermatol.2021.1001","article-title":"Association of hair loss with suicidality and psychological adverse events vs finasteride use","volume":"157","author":"JW Choi","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"9","key":"pone.0309849.ref052","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/pharmaceutics13091410","article-title":"Antioxidant and antiproliferative activity of finasteride against glioblastoma cells","volume":"13","author":"HJ Kim","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"pone.0309849.ref053","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5534\/wjmh.200012","article-title":"Health risks associated with long-term finasteride and dutasteride use: It\u2019s time to sound the alarm","volume":"38","author":"AM Traish","year":"2020","journal-title":"World J Mens Health"},{"issue":"7","key":"pone.0309849.ref054","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00775-019-01692-z","article-title":"Protective effects of finasteride against testosterone-induced calcium oxalate crystallization and crystal-cell adhesion","volume":"24","author":"K Sueksakit","year":"2019","journal-title":"J Biol Inorg Chem"},{"issue":"15","key":"pone.0309849.ref055","doi-asserted-by":"crossref","first-page":"e19486","DOI":"10.1097\/MD.0000000000019486","article-title":"Association of finasteride with prostate cancer: A systematic review and meta-analysis","volume":"99","author":"L Wang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"pone.0309849.ref056","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/diagnostics14111125","article-title":"Clinical presentation of Peyronie\u2019s disease: A retrospective study of 564 cases","volume":"14","author":"G Paulis","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"pone.0309849.ref057","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41443-022-00568-2","article-title":"Are finasteride-related penile curvature\/Peyronie\u2019s disease adverse event reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases","volume":"35","author":"N Schifano","year":"2023","journal-title":"Int J Impot Res"},{"issue":"11","key":"pone.0309849.ref058","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/diagnostics14111125","article-title":"Clinical presentation of Peyronie\u2019s disease: A retrospective study of 564 cases","volume":"14","author":"G Paulis","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"02","key":"pone.0309849.ref059","doi-asserted-by":"crossref","DOI":"10.4172\/2472-1212.1000170","article-title":"Post-finasteride syndrome: About 2 cases and review of the literature","volume":"05","author":"AS Garreton","year":"2016","journal-title":"Andrology (Los Angel)"},{"issue":"1","key":"pone.0309849.ref060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome: a surmountable challenge for clinicians","volume":"113","author":"AM Traish","year":"2020","journal-title":"Fertil Steril"},{"issue":"3","key":"pone.0309849.ref061","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.abd.2020.02.001","article-title":"Post-finasteride syndrome","volume":"95","author":"AFJR Pereira","year":"2020","journal-title":"An Bras Dermatol"},{"issue":"3","key":"pone.0309849.ref062","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1557988314538445","article-title":"Persistent sexual, emotional, and cognitive impairment post-finasteride: A survey of men reporting symptoms","volume":"9","author":"CA Ganzer","year":"2015","journal-title":"Am J Mens Health"},{"issue":"1","key":"pone.0309849.ref063","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome: a surmountable challenge for clinicians","volume":"113","author":"AM Traish","year":"2020","journal-title":"Fertil Steril"},{"key":"pone.0309849.ref064","article-title":"The post-finasteride syndrome: Possible etiological mechanisms and symptoms","author":"HHJ Leliefeld","year":"2023","journal-title":"Int J Impot Res"},{"issue":"10","key":"pone.0309849.ref065","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.21037\/tau-22-92","article-title":"Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients","volume":"11","author":"X Li","year":"2022","journal-title":"Transl Androl Urol"},{"key":"pone.0309849.ref066","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.2147\/CCID.S426747","article-title":"Maculopapular drug eruption caused by finasteride: a case report","volume":"16","author":"H Jia","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"pone.0309849.ref067","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ced.14847","article-title":"Antiandrogen therapy in hidradenitis suppurativa: Finasteride for females","volume":"47","author":"KM Babbush","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"pone.0309849.ref068","doi-asserted-by":"crossref","first-page":"314.e1-314.e7","DOI":"10.1016\/j.clgc.2022.10.014","article-title":"Impact of finasteride on survival in bladder cancer: a retrospective multi-institutional database analysis","volume":"21","author":"H Garg","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"pone.0309849.ref069","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/JU.0000000000001694","article-title":"Finasteride use and risk of bladder cancer in a multiethnic population","volume":"206","author":"D Zhu","year":"2021","journal-title":"J Urol"},{"key":"pone.0309849.ref070","doi-asserted-by":"crossref","first-page":"l1204","DOI":"10.1136\/bmj.l1204","article-title":"Incidence of type 2 diabetes mellitus in men receiving steroid 5\u03b1-reductase inhibitors: population based cohort study","volume":"365","author":"L Wei","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"pone.0309849.ref071","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/ijerph16101726","article-title":"Finasteride-induced inhibition of 5\u03b1-reductase type 2 could lead to kidney damage-animal, experimental study","volume":"16","author":"MS Baig","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"pone.0309849.ref072","first-page":"e60300","article-title":"An unusual case of thalamic stroke in a young adult with patent foramen ovale and finasteride use","volume":"16","author":"SR Gaddameedi","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"pone.0309849.ref073","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s40618-020-01424-0","article-title":"Alterations of gut microbiota composition in post-finasteride patients: a pilot study","volume":"44","author":"F Borgo","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"pone.0309849.ref074","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.3390\/ijms24065904","article-title":"Alteration of gut microbes in benign prostatic hyperplasia model and finasteride treatment model","volume":"24","author":"J An","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"pone.0309849.ref075","doi-asserted-by":"crossref","first-page":"530","DOI":"10.25259\/IJDVL_949_2021","article-title":"Clinical and metabolic characteristics of males with early-onset androgenetic alopecia","volume":"89","author":"K Vinay","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"pone.0309849.ref076","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.fsc.2024.02.006","article-title":"Updated review of treatment of androgenetic alopecia","volume":"32","author":"R Xiao","year":"2024","journal-title":"Facial Plast Surg Clin North Am"},{"key":"pone.0309849.ref077","doi-asserted-by":"crossref","first-page":"1009578","DOI":"10.3389\/fmed.2022.1009578","article-title":"A community-oriented survey on the association between androgenetic alopecia and metabolic syndrome in Chinese people","volume":"9","author":"H Zhu","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"pone.0309849.ref078","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000509063","article-title":"Prescribing habits for androgenic alopecia among dermatologists in Spain in 2019-2020: A cross-sectional study","volume":"6","author":"C Pindado-Ortega","year":"2020","journal-title":"Skin Appendage Disord"},{"key":"pone.0309849.ref079","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/DDDT.S240615","article-title":"Finasteride and its potential for the treatment of female pattern hair loss: Evidence to date","volume":"14","author":"W Iamsumang","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"5 Pt 1","key":"pone.0309849.ref080","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1067\/mjd.2000.107953","article-title":"Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia","volume":"43","author":"VH Price","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"pone.0309849.ref081","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2133.2011.10630.x","article-title":"Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness","volume":"165","author":"R Sinclair","year":"2011","journal-title":"Br J Dermatol"},{"issue":"11","key":"pone.0309849.ref082","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3390\/jcm13113052","article-title":"Safety of antiandrogens for the treatment of female androgenetic alopecia with respect to gynecologic malignancies","volume":"13","author":"SM Seyed Jafari","year":"2024","journal-title":"J Clin Med"},{"issue":"8","key":"pone.0309849.ref083","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.jhered.a110746","article-title":"INHERITANCE OF BALDNESS","volume":"7","author":"D OSBORN","year":"1916","journal-title":"J Hered"},{"issue":"3","key":"pone.0309849.ref084","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/1523-1747.ep12335779","article-title":"Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia","volume":"109","author":"ME Sawaya","year":"1997","journal-title":"J Invest Dermatol"},{"issue":"4","key":"pone.0309849.ref085","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4103\/njcp.njcp_530_22","article-title":"Androgenetic alopecia: Traditional cardiovascular risk factors, metabolic syndrome, and component traits among Nigerian adults","volume":"26","author":"SO Oiwoh","year":"2023","journal-title":"Niger J Clin Pract"},{"key":"pone.0309849.ref086","doi-asserted-by":"crossref","first-page":"1845044","DOI":"10.1155\/2022\/1845044","article-title":"Association between androgenetic alopecia and psychosocial disease burden: A cross-sectional survey among Polish men","author":"R Adamowicz","year":"2022","journal-title":"Dermatol Res Pract"},{"issue":"6","key":"pone.0309849.ref087","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/healthcare12060608","article-title":"Enhancing quality of life and sexual functioning in female androgenetic alopecia: Therapeutic potential of hair follicle-derived stem cells","volume":"12","author":"K Krefft-Trzciniecka","year":"2024","journal-title":"Healthcare (Basel)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:50:08Z","timestamp":1742863808000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309849"}},"subtitle":[],"editor":[{"given":"Roland Eghoghosoa","family":"Akhigbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309849","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}